எண்டோவாஸ்குலர் அறுவை சிகிச்சை நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from எண்டோவாஸ்குலர் அறுவை சிகிச்சை நிபுணர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In எண்டோவாஸ்குலர் அறுவை சிகிச்சை நிபுணர் Today - Breaking & Trending Today

Axio Biosolutions receives CE Certification for next gen wound-care product MaxioCel


Axio Biosolutions receives CE Certification for next gen wound-care product MaxioCel
Axio Biosolutions receives CE Certification for next gen wound-care product MaxioCel
05 February 2021 | News
This next-generation advanced wound-care dressing, MaxioCel is based on Bioactive Microfiber Gelling technology that accelerates healing through quicker granulation
Axio Biosolutions, based in Bengaluru, has announced that it has received CE Certification from Europe for its next generation advanced wound-care product range, MaxioCel. The regulatory approval paves the path for Axio to tap into a fast growing $14 billion advanced wound-care market, globally. 
This next-generation advanced wound-care dressing, MaxioCel is based on Bioactive Microfiber Gelling technology that accelerates healing through quicker granulation. It also provides comfort and has shown faster healing on chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous leg ulcers, cav ....

Kokilaben Dhirubhai Ambani , Leo Mavely , Axio Biosolutions , Raghuram Sekhar , Bioactive Microfiber Gelling , Consultant Vascular , Endovascular Surgeon , Kokilaben Dhirubhai Ambani Hospital , Ce Certification , Wound Care , கோகிலபேண் திருபைய் அம்பானி , ரகுராம் சேகர் , ஆலோசகர் வாஸ்குலர் , எண்டோவாஸ்குலர் அறுவை சிகிச்சை நிபுணர் , கோகிலபேண் திருபைய் அம்பானி மருத்துவமனை , ஸ் சிஇஆர்டிஐஎஃப்ஐசிஏடிஐஓஎன் , காயம் பராமரிப்பு ,

AxioBiosolutions receives European CE mark approval for its advanced woundcare product - MaxioCel; sets eye on Europe and other international markets


MaxioCel- CE Approved Advanced Woundcare product from Axio Biosolutions
AxioBiosolutions receives European CE mark approval for its advanced woundcare product - MaxioCel; sets eye on Europe and other international markets
ANI |
Updated: Feb 05, 2021 18:42 IST
Bengaluru (Karnataka) [India], February 5 (ANI/BusinessWire India): India s homegrown integrated wound-care company, AxioBiosolutions today announced that it has received CE certification from Europe for its next-generation advanced wound care product range, MaxioCel. The regulatory approval paves the path for Axio to tap into a fast-growing USD14 billion advanced wound care market, globally.
This next-generation advanced wound-care dressing, MaxioCel is based on bioactive microfiber gelling technology that accelerates healing through quicker granulation. It also provides comfort and has shown faster healing on chronic wounds, such as pressure ulcers, diabetic foot ul ....

United Kingdom , Pays De La Loire , Clinique Inkerman , Christophe Marchand , Leo Mavely , Raghuram Sekhar , Head Of Center , Businesswire India , Consultant Vascular , Endovascular Surgeon , Kokilaben Dhirubhai Ambani Hospital , Vascular Surgeon , ஒன்றுபட்டது கிஂக்டம் , செலுத்துகிறது டி லா லாய்ர் , கிளினிக் இன்கர்மேன் , கிறிஸ்டோஃப் மார்ச்சண்ட் , ரகுராம் சேகர் , தலை ஆஃப் மையம் , ஆலோசகர் வாஸ்குலர் , எண்டோவாஸ்குலர் அறுவை சிகிச்சை நிபுணர் , கோகிலபேண் திருபைய் அம்பானி மருத்துவமனை , வாஸ்குலர் அறுவை சிகிச்சை நிபுணர் ,

Axio Biosolutions receives CE Certification for its next gen wound-care product MaxioCel


Axio Biosolutions receives CE Certification for next gen wound-care product MaxioCel
Axio Biosolutions receives CE Certification for next gen wound-care product MaxioCel
05 February 2021 | News
This next-generation advanced wound-care dressing, MaxioCel is based on Bioactive Microfiber Gelling technology that accelerates healing through quicker granulation
Axio Biosolutions, based in Bengaluru, has announced that it has received CE Certification from Europe for its next generation advanced wound-care product range, MaxioCel. The regulatory approval paves the path for Axio to tap into a fast growing $14 billion advanced wound-care market, globally. 
This next-generation advanced wound-care dressing, MaxioCel is based on Bioactive Microfiber Gelling technology that accelerates healing through quicker granulation. It also provides comfort and has shown faster healing on chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous leg ulcers, cav ....

Kokilaben Dhirubhai Ambani , Leo Mavely , Axio Biosolutions , Raghuram Sekhar , Bioactive Microfiber Gelling , Consultant Vascular , Endovascular Surgeon , Kokilaben Dhirubhai Ambani Hospital , கோகிலபேண் திருபைய் அம்பானி , ரகுராம் சேகர் , ஆலோசகர் வாஸ்குலர் , எண்டோவாஸ்குலர் அறுவை சிகிச்சை நிபுணர் , கோகிலபேண் திருபைய் அம்பானி மருத்துவமனை ,